COVID-19 – CLIA

A chemiluminescence immunoassay diagnostic test system designed for clinical laboratory use. CLIA technology enables sensitive detection and quantification of various biomarkers and analytes.

A diagnostic solution utilizing chemiluminescence immunoassay technology for rapid and accurate pathogen detection.

Chemiluminescence Immunoassay (CLIA) diagnostic test system. This immunoassay technology utilizes chemiluminescent detection for clinical analysis.

CLIA-certified and ELISA-based diagnostic products for clinical laboratory testing. Compliant with regulatory standards for immunoassay and serological testing.

Light-based immunoassay technology for both high-throughput laboratory analyzers and point-of-care platforms. CLIA offers rapid results with high sensitivity for clinical diagnostics.

Chemiluminescent immunoassay test kits for high-sensitivity detection of analytes in clinical diagnostics. These kits are designed for use in automated laboratory analyzer systems.

CLIA-based diagnostic system for laboratory testing and disease detection. Supports clinical laboratory immunoassay analysis for diagnostic purposes.

CLIA-waived fluorescence PCR detection kit for rapid SARS-CoV-2 identification. The AccuFluor platform delivers real-time PCR results for COVID-19 diagnosis with 510(k) clearance, enabling healthcare facilities to quickly screen patients and guide clinical management decisions.

Rapid immunochromatographic test for qualitative detection of COVID-19 IgG and IgM antibodies in serum, plasma, or whole blood samples. Delivers results in 10-15 minutes, enabling point-of-care screening and confirmation of SARS-CoV-2 infection. CLIA-waived format suitable for clinical laboratories and non-laboratory settings.

CLIA-waived PCR detection kit for simultaneous identification of SARS-CoV-2 and Influenza A/B using direct fluorescence technology. Enables rapid respiratory pathogen screening in clinical and point-of-care settings with streamlined sample-to-result workflow.

CLIA-waived molecular diagnostic test delivering rapid infectious disease results in approximately 15 minutes. Combines detection of influenza A/B, respiratory syncytial virus, and COVID-19 in a single assay.

A rapid immunoassay for simultaneous detection and differential diagnosis of SARS-CoV-2, influenza type A, and type B antigens from nasal and nasopharyngeal swab specimens. Provides results in 15 minutes with FDA 510(k) clearance and CLIA waiver status.